Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proprietary Name Evaluation Guidance Will Detail New FDA Review Process

Executive Summary

FDA expects to publish a draft guidance on "Evaluating Proprietary Names" in the next few months to explain its new procedures for evaluating proposed drug names in order to avoid medication errors.

You may also be interested in...



FDA Drug Name Policy "Discourages" New Brand Names For Old Ingredients

FDA's Office of Postmarketing Drug Risk Assessment is "discouraging" applications that would create a new brand name for an existing active ingredient.

FDA Drug Name Policy "Discourages" New Brand Names For Old Ingredients

FDA's Office of Postmarketing Drug Risk Assessment is "discouraging" applications that would create a new brand name for an existing active ingredient.

Off Label Drug Use Data To Be Required In Periodic Safety Updates - FDA

Pharmaceutical companies will be asked to provide postmarketing drug usage information in their periodic safety update reports, including use in off label indications, under a proposed FDA rule due out later this year.

UsernamePublicRestriction

Register

PS035796

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel